Company Overview and News

to your dashboard

Headline News

This Pharma Stock Is Up 111% and Investors Are Wondering What's Next - Bloomberg

2017-10-17 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (96-0)

Global Idiopathic Pulmonary Fibrosis Market Expected to Reach $3,569 Million by 2023 - Allied Market Research

2017-10-12 prnewswire
According to a new report published by Allied Market Research, titled, "Idiopathic Pulmonary Fibrosis Market by Type of Drug: Global Opportunity Analysis and Industry Forecast, 2017-2023," the global idiopathic pulmonary fibrosis market was valued at $1,616 million in 2016, and is projected to reach $3,569 million by 2023, growing at a CAGR of 11.9% from 2017 to 2023. Perifenidone held more than half share of the total market in 2016. (78-0)

Transcript: MiB Richard Thaler, Laureate - The Big Picture

2017-10-10 ritholtz
Given that the Royal Swedish Academy of Sciences Sveriges Riksbank Prize in Economic Sciences went to Richard Thaler yesterday, I thought it might be timely to access the transcript of our MIB interview from 2015. You can also stream it above, or listen on iTunes and Bloomberg. (6-0)

AbbVie Transitions To Growth Stock From Income Play

2017-09-28 seekingalpha
With a positive press release today regarding its flagship drug Humira suggesting it can avoid US biosimilar competition until 2023, ABBV trades at 22X TTM GAAP EPS. (215-0)

MorphoSys and Galapagos Report First Promising Signs of Clinical Activity in a Phase 1 Study With IL-17C-Antibody MOR106 in Atopic Dermatitis Patients

2017-09-27 accesswire
- At the highest dose level, 5 out of 6 patients (83%) reached an improvement of at least 50% in atopic dermatitis symptoms (EASI-50) by week 4 (6-0)

Why Gilead May Regain Growth Stock Status

2017-09-20 seekingalpha
GILD has strong assets in HIV/AIDS and HCV, but can it get revalued as a growth stock again? (20-0)

Faison's Weekend Review And Scans

2017-09-16 seekingalpha
In this weekly series, I present a few ideas from scans for reader discussion and further due diligence. (16-8)

My Journey To Financial Independence: 81-Stock August Portfolio Update - Buying Gilead And Growth Stocks

2017-09-15 seekingalpha
Appreciating EUR/USD continues to drag down portfolio and dividend values with Gifted Working Time crossing the 2-week mark.

Biotech Stock Roundup: Regeneron Drops RSV Antibody, Gilead HIV Drug Gets Priority Review

2017-08-16 zacks
With earnings season drawing to a close, focus is back on pipeline and regulatory updates. While Regeneron Pharmaceuticals (REGN - Free Report) , which has several pipeline catalysts lined up for the second half of the year, reported data on one of its late-stage pipeline candidates, Gilead Sciences (GILD - Free Report) got priority review for its investigational HIV treatment. Recap of the Week’s Most Important Stories Regeneron Shelves RSV Antibody on Study Failure: Regeneron’s investigational antibody, suptavumab (REGN2222), for respiratory syncytial virus (RSV), failed to meet the primary endpoint in a late-stage study conducted in infants.

Ecuador detains Chinese boat with endangered sharks - BBC News

Authorities in Ecuador have detained the crew of a Chinese fishing boat suspected to have caught endangered sharks in the Galapagos Islands.

ROTY Volume 1 Edition 20: Introducing The Contenders List, Updates And A Potential Year-End Runner

2017-08-14 seekingalpha
Additionally, we are selling out one position with catalysts that are farther out in order to purchase shares in an idea with more immediate upside potential.

Fibrogen And Galapagos Raise Lung Disease Hopes

2017-08-14 seekingalpha
Important new data on novel idiopathic pulmonary fibrosis candidates look set to continue to emerge in the wake of two encouraging reports in the past couple of weeks. Biogen (NASDAQ:BIIB), Promedior, Sanofi (NYSE:SNY) and Roche (OTCQX:RHHBY) are all due to unveil fresh information from mid-stage candidates before the end of the year.

3 Things In Biotech You Should Learn Today: August 14, 2017

2017-08-14 seekingalpha
Welcome to another edition of "3 Things in Biotech You Should Learn Today," a daily digest dedicated to helping you mine recent news in the biotech and pharma industries!

Snippet Roundup: A Small Success For Galapagos And A Big One For Karius

2017-08-11 seekingalpha
Welcome to your weekly roundup of EP Vantage's snippets - short takes on smaller news items.

Galapagos: A Strong Contender For IPF

2017-08-11 seekingalpha
There are a few competitors in the space, but the market opportunity is still big enough for many.

ROTY Edition 1 Volume 19: Being Nimble In Times Of Volatility And Updates

2017-08-11 seekingalpha
Two promising positions are let go of (for now) and relegated to the Contenders List.  I will keep a close eye on them.

Galapagos' Phase II Results With GLPG1690 are 'Extremely Exciting'

2017-08-10 biospace
Webcast presentation of the results to be held tomorrow 10 August, 14.00 CET/8 AM EDT, +32 2 404 0659, access code 2084135; more call number info further down

Is a Surprise Coming for Galapagos (GLPG) This Earnings Season?

2017-08-03 zacks
Investors are always looking for stocks that are poised to beat at earnings season and Galapagos NV (GLPG - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report. That is because Galapagos is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings—with the most up-to-date information possible—is a pretty good indicator of some favorable trends underneath the surface for GLPG in this report.

Should You Buy Vertex Pharmaceuticals Incorporated (VRTX) Stock? 3 Pros, 3 Cons | InvestorPlace

2017-08-03 investorplace
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has shined bright within the biotech industry this year. VRTX stock has more than doubled over the past 12 months. That stands in stark contrast to the sector, which in general has struggled due to high valuations and political uncertainty regarding healthcare reform.

Quanta Services (PWR) Q2 Earnings: What's in the Cards?

2017-08-01 zacks
Quanta Services, Inc. (PWR - Free Report) is slated to report second-quarter 2017 results before the opening bell on Aug 3.

GoPro (GPRO) to Report Q2 Earnings: A Beat in Store?

2017-08-01 zacks
GoPro, Inc. (GPRO - Free Report) is slated to release second-quarter 2017 results, after the closing bell on Aug 3.

Match Group (MTCH) to Report Q2 Earnings: What's in Store?

2017-07-31 zacks
Match Group, Inc. (MTCH - Free Report) is set to report second-quarter 2017 earnings results on Aug 1.

Vertex (VRTX) Q2 Earnings Top on Solid Cystic Fibrosis Sales

2017-07-27 zacks
Vertex Pharmaceuticals Incorporated (VRTX - Free Report) reported second-quarter 2017 earnings per share of 10 cents (including the impact of stock-based compensation expense), which beat the Zacks Consensus Estimate of 6 cents. Notably, the company had posted a loss of 1 cent in the year-ago quarter. Strong product revenues led to higher profits in the quarter.

Biotech Bonanza: The Next Leg Up

2017-07-25 seekingalpha
The Biotechnology sector remains one of the top performing sectors this year with the benchmark Nasdaq Biotechnology Index, as represented by ETF (IBB), gaining 17% in the first-half. The index though still remains ~29% down from its all-time high achieved in mid-2015. In comparison, the S&P 500 (SPY) was up 8%, and the Nasdaq Composite (QQQ) up 14%, in the first-half.

Will Flowserve (FLS) Pull Off a Surprise in Q2 Earnings?

2017-07-25 zacks
We expect Flowserve Corporation (FLS - Free Report) to beat earnings when it reports second-quarter 2017 results on Jul 27, after the closing bell.